Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma
Sponsor: Chang Gung Memorial Hospital
Summary
The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.
Official title: A Phase II Trial, Sequential Treatments of Dendritic Cell Vaccination Followed by Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2019-07-01
Completion Date
2028-02
Last Updated
2026-07-24
Healthy Volunteers
No
Conditions
Interventions
dendritic cells
autologous dendritic cell vaccination
Locations (1)
Chang-Gung Memorial Hospital
Taoyuan, Taiwan